by Rod Raynovich | Apr 21, 2010 | BIOgraph
Healthcare Reform Impact on Gilead HIV Product Sales Surprises Analysts Gilead Sciences (GILD) lowered its 2010 sales forecast to a range of $7.4-$7.5B from $7.6-$7.8B citing recently enacted healthcare legislation. Net income for the quarter ended March 31 jumped...